Fibroblast Growth Factor Stocks List

Related ETFs - A few ETFs which own one or more of the above listed Fibroblast Growth Factor stocks.

Fibroblast Growth Factor Stocks Recent News

Date Stock Title
May 3 RARE Ultragenyx Pharmaceutical Inc (RARE) (Q1 2024) Earnings Call Transcript Highlights: Key ...
May 3 RARE Ultragenyx (RARE) Q1 Loss Wider Than Expected, Revenues Rise Y/Y
May 3 RLAY Relay Therapeutics GAAP EPS of -$0.62 beats by $0.10, revenue of $10.01M beats by $9.09M
May 3 RARE Ultragenyx Pharmaceutical, Inc. (RARE) Q1 2024 Earnings Call Transcript
May 2 RLAY Relay Therapeutics Outperforms Revenue Expectations in Q1 2024
May 2 RARE Ultragenyx Pharmaceutical Inc (RARE) Q1 2024 Earnings: Misses EPS Estimates, Revenue Grows ...
May 2 RLAY Relay Therapeutics, Inc. (RLAY) Reports Q1 Loss, Tops Revenue Estimates
May 2 RLAY Relay Therapeutics GAAP EPS of -$0.62 beats by $0.08, revenue of $10M beats by $9.89M
May 2 RLAY Relay Therapeutics Reports First Quarter 2024 Financial Results and Corporate Highlights
May 2 RARE Ultragenyx Pharmaceutical GAAP EPS of -$2.03 misses by $0.28, revenue of $108.8M misses by $7.64M
May 2 RARE Ultragenyx Reports First Quarter 2024 Financial Results and Corporate Update
May 2 FUSN Fusion Pharmaceuticals Inc. (FUSN) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
May 1 RARE Ultragenyx Pharmaceutical Q1 2024 Earnings Preview
Apr 30 RARE Ultragenyx Issues 2023 Corporate Responsibility Report, Showcasing Commitment to Improving Equity and Access to Innovation in Rare Disease
Apr 30 RARE Ultragenyx Announces Completion of Enrollment in Phase 3 Orbit and Cosmic Studies Evaluating Setrusumab (UX143) for the Treatment of Osteogenesis Imperfecta (OI)
Fibroblast Growth Factor

The fibroblast growth factors (FGF) are a family of cell signalling proteins that are involved in a wide variety of processes, most notably as crucial elements for normal development. Any irregularities in their function lead to a range of developmental defects. These growth factors generally act as systemic or locally circulating molecules of extracellular origin that activate cell surface receptors. A defining property of FGFs is that they bind to heparin and heparan sulfate. Thus, some of them are found to be sequestered in the extracellular matrix of tissues that contains heparan sulfate proteoglycans and they are released locally upon injury or tissue remodeling.

Browse All Tags